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Abstract A number of plasma lipid parameters have been
used to estimate cardiovascular risk and to be targets for treat-
ment to reduce risk. Most risk algorithms are based on total
cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-
C) and high-density lipoprotein cholesterol (HDL-C), and most
intervention trials have targeted the LDL-C levels. Emerging
measures, which in some cases may be better for risk calcula-
tion and as alternative treatment targets, are apolipoprotein B
and non-HDL-C. Other lipid measures that may contribute in
risk analysis are triglycerides (TG), lipoprotein(a), and
lipoprotein-associated phospholipase A2. The primary treat-
ment target in cardiovascular prevention is LDL-C, and poten-
tial alternative targets are apoB and non-HDL-C. In selected
individuals at high cardiovascular (CV) risk, TG should be
targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C
or apoB/apoAI are not recommended as treatment targets.
Lipids should be monitored during titration to targets. There-
after, lipids should be checked at least once a year or more
frequently to improve treatment adherence if indicated. Mon-
itoring of muscle and liver enzymes should be done before the
start of treatment. In stable conditions during treatment, the
focus should be on clinical symptoms that may alert muscle or
liver complications. Routinemeasurement of CK orALT is not
necessary during treatment with statins.
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Introduction
An overwhelming number of studies in the past de-
cades have established dyslipidemia as the major risk
factor for the development of atherosclerotic cardiovascular
disease. Recent reductions in plasma cholesterol levels
have contributed to a dramatic decrease in the incidence of
premature coronary heart disease in the western world [1, 2].
However, atherosclerotic cardiovascular disease remains the
main killer in the western world and its impact is increasing
worldwide.
Although lifestyle factors, primarily dietary habits, are the
fundamental targets for lipid lowering, the development of
pharmacological interventions—in particular, statins—has
been a major contributor to reduction of disease. Statins are
now used by millions of people worldwide and their dramat-
ic effect on cardiovascular disease has been shown in a large
number of trials and also in meta-analyses. Based on results
from cohort studies the total CV risk can be estimated with
risk estimation tools that have been developed for that pur-
pose. Armed with increased knowledge of lipid and lipopro-
tein metabolism and of the role of lipoproteins in the devel-
opment of atherosclerosis, it is important to determine which
lipid measurements are the most informative in risk estima-
tion and which lipid measures are the best to target for
therapy. An active discussion on these subjects has taken
place in recent years. Furthermore, recent guidelines suggest
more intense lipid lowering in selected patients [3•, 4].
However, intense lipid lowering increases the risk of side
effects from pharmacological treatment and the question on
how to monitor safety during treatment has become more
important.
In this review, the advantages and disadvantages of the
different lipid measures and lipid targets are discussed in
relation to the current literature. Safety monitoring is also
discussed and updated with regard to recent studies.
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Which Lipid Parameters Should Be Used to Estimate
Cardiovascular Risk?
A first step in cardiovascular prevention is to estimate the
risk for cardiovascular disease (CVD) in the individual.
Performing a risk analysis is important from several aspects.
First, the intervention can be targeted to subjects with high
risk. The absolute reduction of CV events is higher in the
high risk patients. Consequently, the cost per prevented
event is lower in subjects with high risk. Risk analysis is
also an important tool for the design of prevention. Which
factors should be treated? Furthermore, the level of target to
reach can be adapted to the risk level. Risk analysis will also
educate the patient to improve the adherence to treatment.
Some patients have an underlying condition associated with
high risk, and in these cases no further risk analysis has to be
done. This is the case in patients with established CVD,
diabetes, chronic kidney disease (CKD), or markedly elevat-
ed single risk factor, such as familial hypercholesterolemia.
A number of plasma lipid parameters have been used to
estimate cardiovascular risk and to be targets for treatment
to reduce risk. Most risk algorithms, such as SCORE, Fra-
mingham score and Reynolds Risk score, are based on total
cholesterol (T-C), or low-density lipoprotein cholesterol
(LDL-C) and high-density lipoprotein cholesterol (HDL-C),
and most intervention trials have targeted the LDL-C levels.
However, a disadvantage of LDL-C is that it does not include
the triglyceride-rich atherogenic particles intermediate-density
lipoprotein (IDL) and very low-density lipoprotein (VLDL)
[5]. These are better described using non-HDL-C (calculated
as T-C minus HDL-C) or apolipoprotein B (apoB; the protein
component of atherogenic lipoproteins). Because there is only
one apoB molecule per lipoprotein particle, apoB concentra-
tion is a measure of particle number. Non-HDL-C and apoB
have therefore been suggested as alternative or even preferred
lipid variables for risk estimation [6, 7].
The use of non-HDL-C and apoB may be especially
advantageous in patients with combined hyperlipidemia,
such as in the metabolic syndrome or type 2 diabetes. Fur-
thermore, LDL-C cannot be calculated with the Friedewald
formula [3•] in hypertriglyceridemia ( TG >400 mg/dl or
>4.5 mmol/L). A number of studies indicate that apoB is a
better predictor than cholesterol measures of cardiovascular
risk [6, 7], most recently in a meta-analysis of 233,455
subjects and 22,950 events [8]. However, several analyses
do not support the conclusion that apoB adds to the infor-
mation given by the lipid markers including non-HDL-C [9,
10••, 11]. Some studies support non-HDL-C and apoB as
better risk indicators in obesity or diabetes [12, 13], but 1
study on obesity reports that apolipoproteins do not contrib-
ute to risk prediction [11]. The choice between assessments
of cholesterol and apolipoproteins for risk analysis seems to
be more dependent on practical considerations, such as cost,
availability and tradition, than on major differences in risk
estimation [9].
Low HDL-C and elevated triglycerides (TG) are both
independent risk factors for cardiovascular disease. HDL-C
is included in several of the risk algorithms and should
always be analyzed to evaluate cardiovascular risk [3•, 4].
Although not so strong when corrected for other risk factors,
TG also contributes to risk assessment [14]. Furthermore low
HDL-C and high TG are ingredients of the dyslipidemia
often associated with the metabolic syndrome and type 2
diabetes. HDL-C and TG therefore may indicate the cause of
the dyslipidemia and also guide the selection of therapy.
Patients with very high TG (>10 mmol/L or >900 mg/dL)
should immediately start therapy because of the risk of
pancreatitis [15].
The different ratios (apoB/apoAI, T-C/HDL-C, non-HDL-
C/HDL-C) give similar information as their components, but
may be practical for screening. However, focusing on ratios
may hide essential diagnostic information.
New lipid markers for risk estimation have recently
emerged, but most of the new variables (such as lipoprotein
subclasses and particle size) have yet to prove that they
contribute to the total risk estimation above that provided
by conventional lipid analyses [16]. In a meta-analysis of
165,544 subjects and 15,126 events, only 2 markers signif-
icantly improved the prediction of future cardiovascular
events: lipoprotein(a) (Lp(a)) and lipoprotein-associated
phospholipase A2 (LpPLA2) [10••]. This is supported by a
recent population study from Copenhagen, which suggests
that extreme Lp(a) levels substantially improves CVD pre-
diction [17]. Lp(a) has been discussed as a risk factor for
decades, and recent data from genetic analyses have shown
that Lp(a) most probably has an etiologic role in atheroscle-
rosis [18, 19]. Lp(a) levels are highly genetically deter-
mined and may add information on risk especially in
subjects with a family history of cardiovascular disease.
Lp-PLA2 also seems to have an etiological role and its
potential as a therapeutic target is now being studied in clinical
trials [20, 21].
Which Lipid Parameters Should be Targeted
by Treatment to Reduce Cardiovascular Risk?
The primary reason to monitor lipids during lipid-lowering
treatment should be to evaluate if treatment targets have been
reached. Guidelines for target levels of plasma lipids are
based on results from randomized controlled trials and from
meta-analyses. The absolute target levels still are under debate,
but most guidelines have similar approaches in identifying and
defining targets [4, 22–26] and most identify LDL-C levels as
the primary target for treatment. In European guidelines [3•, 4],
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the target of LDL-C is adapted to total CV risk level (Table 1)
with a lower level for subjects with very high cardiovascular
risk (Table 2). The lower targets suggested in recent guidelines
are based on studies comparing different treatment regimens
and on meta-analyses of a large number of statin trials [27••,
28]. Although these studies give good support for the lowLDL-
C targets, the “lower the better” approach is still under debate
[29, 30]. ApoB and non-HDL-C have not been studied as
primary targets in randomized studies, but post-hoc analyses
suggest that both may be used [31–33] and these analyses form
the basis for target levels in guidelines (Table 2).
The concept that more may be achieved with more intense
treatment is supported by observations on residual risk dur-
ing statin treatment. In 1 recent analysis of the JUPITER trial
on treatment levels of LDL-C, non-HDL-C, and apoB were
found to identify residual risk [34]. Similar observations are
reported from the Treating to New Targets (TNT) study [32]
and in a recent meta-analysis [33] on association of LDL-C,
non-HDL-C and apoB levels with cardiovascular events
among patients treated with statins.
Should HDL-C be a target for treatment and monitored
during therapy? Recent guidelines do not suggest HDL-C as
a treatment target, despite its importance as a marker for
future cardiovascular disease [3•, 4]. However, based on
epidemiological data, optimal HDL levels are suggested to
be >1.0 mmol/L( >40 mg/dL) for men and >1.2 mmol/L(
>45 mg/dL) for women. The potent HDL-elevating drugs
cholesteryl ester transfer protein (CETP) inhibitors have not
been found to reduce cardiovascular disease; the first CETP
inhibitor tested actually showed increased mortality in the
treated group, probably due to off-target effects [35], and a
study with another CETP inhibitor was prematurely termi-
nated due to lack of effect [36]. Furthermore, genetic studies
using mendelian randomization do not support HDL as a
direct causative agent for disease [37].
The data supporting TG as a target for drug treatment are
less robust than for LDL-C. The optimal TG level is sug-
gested to be below 1.7 mmol/L (150 mg/dL), primarily based
on epidemiological data [22]. European guidelines suggest
that the use of drugs should only be considered if TG is over
2.3 mmol/L (200 mg/dL) and cannot be lowered by life-style
changes, and if the subject is at high risk of cardiovascular
disease [22].
Levels of Lp(a) above 30 mg/dL are associated with
increased risk of cardiovascular disease, but there is no
evidence at present to show that intervention against high
Lp(a) reduces cardiovascular risk. Thus, no target level for
treatment has been recommended [18, 19].
Selection of Drugs
Five main groups of pharmacological agents are, at present,
available for the treatment of hyperlipidemia.
Statins
Statins (HMG-CoA-reductase inhibitors: simvastatin, ator-
vastatin, pravastatin, rosuvastatin, fluvastatin, lovastatin, and
pitavastatin) cause a reduction in intracellular cholesterol
levels, leading to increased LDL receptor expression on
hepatocyte membranes with a subsequent reduction in the
circulating levels of apoB-containing lipoproteins (LDL,
IDL, VLDL). A large body of evidence shows that statins
are effective in the reduction of LDL-C and cardiovascular
events [27••, 28], and statins are the first-line treatment for
individuals with high levels of LDL-C or combined hyperlip-
idemia both in primary and secondary prevention. Depending
on dose and potency of the statin (rosuvastatin, atorvastatin
and pitavastatin being the most potent), a reduction of LDL-C
of up to 55 % may be achieved [38]. In patients with moder-
ately elevated TG, statins may reduce TG by about 15 %–
20 %. A moderate increase in HDL-C (5 %–10 %) is also
achieved.
Ezetimibe
Ezetimibe inhibits intestinal and biliary cholesterol absorp-
tion, probably via interaction with Niemann-Pick C1-like
protein 1 (NPC1L1) [39]. It reduces absorption of dietary
Table 1 Global risk stratification according to the European guidelines on cardiovascular disease prevention in clinical practice (2012)




≥1 % to <5 %
High ≥5 % to<0 %, or markedly elevated single risk factor (eg, familial dyslipidemia or severe hypertension), or type 1 or 2 diabetes
without CV risk factors or target organ damage, or moderate CKD (GFR 30–59 mL/min/1,73 m2).
Very high ≥10 %, or documented CVD, or type 1 or 2 diabetes with 1 or more CV risk factors and/or organ damage, or severe CKD(GFR
<30 mL/min/1.73 m2)
(Modified from [4]).
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and biliary cholesterol as it blocks the enterohepatic circula-
tion, and reduced cholesterol transport to the liver induces
increased LDL receptor expression on hepatocytes.
Ezetimibe induces a reduction of LDL-C of approximately
15 %–20 %. It is primarily used in combination with a statin
with a 22 %–26 % reduction of LDL-C beyond that obtained
by statin alone [40, 41]. Effects on cardiovascular end-points
in randomized trials are still lacking, but 1 study, IMPROVE-
IT, will report in 2013 [42].
Bile Acid Sequestrants
Bile acid sequestrants (cholestyramine, colestipol, and
colesevelam) remove bile acids from the enterohepatic cir-
culation. Because bile acids are synthesized from cholester-
ol, LDL receptor expression is increased in the bile-
depleted liver resulting in reduced LDL-C levels. An 18 %–
25 % reduction in LDL-C has been observed with bile
acid sequestrants, and they are primarily used to reduce
LDL-C in patients intolerant to statins or in combina-
tion, where targets are not reached with statin alone. Bile acid
sequestrants have been shown to reduce cardiovascular mor-
bidity [43].
Niacin
Niacin (also known as vitamin B3 or nicotinic acid) has a
broad effect on modulating lipoprotein levels (at a dosage of
2 g/day): it increases HDL-C by 15 %–35 % and reduces TG
by 20 %–40 % and LDL-C by 15 %–18 %. The effect on
LDL-C and TG is primarily mediated by retention of VLDL
by the liver. Niacin is used in patients with hypertriglyc-
eridemia or combined hyperlipidemia often in combination
with a statin. In clinical trials, niacin has been shown to
reduce cardiovascular morbidity but not mortality [44]. Ni-
acin is the most potent drug to increase HDL-C and at
present the only drug that reduces Lp(a). The clinical signif-
icance of this, however, has not been shown. The recent
failure of the AIM-HIGH [45] and the HPS-2 THRIVE
[46](THRIVE home Page: www.thrivestudy.org) studies
makes the future of niacin in cardiovascular prevention
doubtful .
Fibrates
Fibrates (fenofibrate, gemfibrozil, clofibrate, ciprofibrate,
and bezafibrate) cause a reduction in the levels of TG-rich
particles, both in the fasting and in the postprandial state, due
to their agonist effect on peroxisome proliferator–activated
receptor (PPAR)α. Fibrates also result in a modest increase
of HDL-C. They are primarily used in individuals with
hypertriglyceridemia or in high-risk patients with mixed
hyperlipidemia [44]. In clinical trials fibrates have shown a
reduction in the rate of non fatal myocardial infarction,
however, often only in post-hoc analyses [47].
Combination Therapy
In many cases targets are not reached with the highest dose of
1 drug, or the dose has to be kept low due to side effects. In
these cases combination therapy should be considered. How-
ever, the number of clinical trials showing clinical benefit
from combination therapy is limited. In patients with hyper-
cholesterolemia statin can be combined with a bile acid
sequestrant or a cholesterol absorption inhibitor. In the
SHARP trial the combination of simvastatin and ezetimibe
was shown to reduce CVD in patients with CKD [48]. The
combination of fibrate and statin has been shown to improve
reduction in both LDL-C and TG. The results from clinical
trials have not shown a reduction in CV. However, in post
hoc analyses from studies patients with high TG and low
HDL seem to benefit from the combination of fenofibrate
and a statin. Therefore the combination may be considered in
certain patients at high risk [5]. In combination therapy drug
interactions have to be considered. This especially refers to
the interaction between statins and fibrates, since both drugs
are associated with increased risk of myopathy (see below).
Furthermore the combination of niacin/laropiprant and statin
is associated with increased frequency of myopathy as
shown in HPS2-THRIVE [46].
Table 2 Treatment targets for LDL-C, non-HDL-C, and apoB at different levels of cardiovascular risk
Risk level Treatment targets
LDL-C Non-HDL-C ApoB
Moderate <3.0 mmol/L (<115 mg/dL) <3.8 mmol/L (<145 mg/dL)
High <2.5 mmol/L (<100 mg/dL) <3.3 mmol/L (<130 mg/dL) <100 mg/dL
Very high <1.8 mmol/L (<70 mg/dL) <2.6 mmol/L (<100 mg/dL) <80 mg/dL
Desirable level of TG <1.7 mmol/L (<150 mg/dL).
Desirable level of HDL-C >1.0 mmol/L (>40 mg/dL) for men, >1.2 mmol/L (>45 mg/dL) for women.
Modified from [61].
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How Should Lipids Be Monitored?
Before initiation of therapy, lipids should be measured at
least twice and the lipid levels evaluated as a part of global
risk estimation, preferentially using 1 of the available risk
calculators such as SCORE [4]. Dyslipidemia should be
diagnosed with complete lipid status including (at least) T-
C, LDL-C, TG, and HDL-C (similar information may be
obtained by non-HDL-C, apoB, and apoAI). Possible under-
lying metabolic disturbances and other diseases should be
excluded by measuring (at least) glucose, alanine, and aspar-
tate transaminases (ALT and AST), creatinine and thyroid-
stimulating hormone.
Lipids should be checked 6–8 weeks after initiation of
therapy and also after any change to drug therapy, such as
dose change, change of compound, or starting combination
therapy. The effect of statins is seen already after 4 weeks but
other drugs may take longer. A longer time-frame is required
to see the effect of lifestyle changes such as diet, weight
reduction, and increased physical activity. Patients who have
reached therapeutic goals and are in a stable condition often
only need to be checked once a year. However, more fre-
quent controls should be considered to improve adherence to
lifestyle changes and to pharmacological treatment. The
importance of regular lipid monitoring has been reported in
several studies [49].
The lipid parameters that are analyzed in the regular
checks should be determined by the original dyslipidemia.
As a minimum, T-C should be measured, but better manage-
ment and probably better patient compliance are achieved if
a full lipid profile (including LDL-C, HDL-C, and TG) is
obtained. ApoB and non-HDL-C are alternative measures
that may be used, especially in patients with hypertriglyc-
eridemia. Non-HDL-C is a good marker for TG and TG-rich
remnant particles [5, 9]. The experience with apoB is, how-
ever, still limited in routine clinical settings.
A disadvantage of measuring a single plasma lipid at 1
occasion is that there is considerable intra-individual varia-
tion, estimated at about 7 % for cholesterol and 28 % for
triglycerides [50]. This variation results from analytical er-
ror, individual variation due to other factors and seasonal
variation, with highest levels during the summer and lowest
during the winter [51]. These intra-individual variations
should be taken into account, and small changes should be
checked before therapy is changed.
Safety Monitoring
Statins
Statins are considered to be relatively safe drugs. The most
important side effects, which should be monitored, are muscle
or liver related. Side effects are dose dependent and influenced
by other conditions such as: age, female gender, small body
size, alcohol abuse, presence of multisystemic diseases, re-
duced kidney or liver function, and interaction with other
drugs.
Monitoring of Muscle-Related Side Effects
Muscle symptoms are the most common and serious side
effects of statins [52, 53•], leading to poor compliance or
statin intolerance. It is essential during follow up that both
the patient and the physician are aware of the possible
association between muscle symptoms and statins, since
the symptoms often are vague and difficult to interpret. As
long as levels of the circulating muscle enzyme creatine
kinase (CK) remain normal, statin therapy may continue if
the symptoms are acceptable to the patient (Table 3).
Myalgia may be defined as the presence of muscle pain or
tenderness without elevation of CK. The frequency of myal-
gia varies from 1.5 %–5 % in randomized studies [54, 55] to
5 %–10 % in observational studies [56, 57]. The symptoms
are most often located to bigger proximal muscle groups, but
can also have other locations [53•]. They often appear within
a couple of months of starting therapy or after dose adjust-
ment. The cause of the symptoms is unclear [53•, 58].
Severe myopathy (rhabdomyolysis) is characterized by
severe muscular pain, with an elevation of the muscle en-
zymes to more than 10 times the upper limit of normal. In
addition, the patient may develop myoglobinuria and, even-
tually, renal insufficiency. The incidence of rhabdomyolysis
has been estimated to be 1–3 cases per 100,000 patient years
[54]. Death occurring after rhabdomyolysis has been esti-
mated to occur in 0.15 per million treated patients [59].
The monitoring of possible muscular side effects should
be especially directed towards the risk groups. Myalgia is
more common in physically active subjects. Myopathy is
more common in patients with previously high CK, women,
the elderly, and patients with reduced renal or liver function.
The genetic background is also involved in the development
of muscular symptoms since family history is a risk factor.
Indeed, genetic variations in transport proteins and cyto-
chrome P450 (CYP) enzymes have been identified as risk
factors for myopathy [53•, 58].
The most common cause of severe myopathy is probably
interactions with other drugs. Many drugs are dependent on
CYP3A4 for their catabolism, and these may thus interact
with the CYP3A4-dependent statins simvastatin, lovastatin,
and atorvastatin. Pravastatin, rosuvastatin, and fluvastatin are
catabolized through other enzymes (CYP2C9). Statins com-
bined with gemfibrozil are associated with increased risk of
rhabdomyolysis while this risk is much smaller when statins
are combined with fenofibrate or niacin. Examples of drugs
that potentially interact with statins are given in Table 4.
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The risk for myopathy increases with dose [60]. There is
no conclusive evidence that risk for myopathy varies be-
tween the statins when used at regular doses, with the excep-
tion of cerivastatin. However, the US Food and Drug Ad-
ministration (FDA) recently concluded that high-dose sim-
vastatin (80 mg/d) is associated with higher risk and should
not be used; the interaction between lower doses of simva-
statin and other drugs was also emphasized [61].
In addition to actively asking for symptoms, CK elevation
is the most important tool to detect severe myopathy. CK
should be checked before initiation of therapy; if elevated, it
should be checked again and, if still elevated, the use of
statins should be reconsidered. CK elevations are often seen
spontaneously and can be caused by several factors such as
high physical activity. Therefore, CK elevation without
symptoms has a very poor specificity, and a routine check
of CK is not recommended. According to current guidelines,
CK should be checked if muscle symptoms appear. If CK is
less than 5 times the upper limit of normal, continue statins
and monitor CK. If CK is over 5 times the upper limit, stop
treatment, check renal function, and monitor CK every 2-
weeks (Table 3). It is also important to consider other
reasons for the CK elevation [3•, 4].
Monitoring of Liver Enzymes
Treatment with statins tends to increase hepatic transami-
nases. This effect is dose-dependent and meta-analyses of
randomized placebo controlled trials demonstrate that low to
moderate doses of statins are not associated with clinically
significant elevations in transaminases (>3× ULN) [62, 63].
Maximal doses of all statins are associated with a modest but
significant elevation of transaminase levels [63, 64]. Until
recently, guidelines have recommended that liver enzymes
should be monitored before statin treatment and regularly
during treatment [3•]. In 2006, the National Lipid Associa-
tion Statin Safety Task Force published an assessment of
statin safety as well as conclusions and recommendations
[65, 66]. The task force found that significant liver disease
caused by statin treatment was extremely uncommon, and
elevations of liver enzymes will often resolve with continued
therapy. Based on this information FDA in 2012 changed the
recommendation regarding control of liver enzymes during
statin therapy. The new recommendation says that hepatic
function test should be performed before starting therapy and
as clinically indicated thereafter, not as a routine monitoring
(FDA Drug Safety Communication (February 28, 2012)
[67]. Special attention should be directed towards clinical
symptoms in patients with increased risk for statin related
side effects.
The presence of non alcoholic fatty liver disease should
not be a contraindication to statin therapy [68–70]. Moder-
ately elevated liver enzymes do not seem to be associated
Table 3 Safety monitoring dur-
ing treatment with lipid lowering
drugs
ALT alanine aminotransferase,
CK creatinine kinase,ULN upper
limit of normal
Modified from [3•].
Monitoring liver enzyme (ALT) during treatment with statins.
• Before treatment.
• During treatment routine check is not necessary.
• Stop treatment if signs/symptoms of liver disease occur and measure liver function.
Monitoring of muscle enzyme (CK) during treatment with statins.
• Before treatment
• If baseline CK is >5×ULN, do not start therapy, recheck.
• Routine monitoring is not necessary.
• Measure CK if patient develops myalgia.
What if CK becomes elevated during treatment?
• If CK >5×ULN
○ Stop treatment, check renal function and monitor CK every 2 wk.
○ Consider CK elevation for other reasons, such as muscle exertion.
○ Consider secondary causes of CK elevation if CK remains elevated
• If CK <5×ULN
○ If no muscle symptoms, continue therapy. Alert patient to report symptoms. Consider check of CK.
○ If symptoms, monitor symptoms and CK regularly.
Table 4 Drugs that potentially interact with statins leading to increased
risk of myopathy and rhabdomyolysis







HIV protease inhibitors Gemfibrozil
Modified from [61].
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with increased risk of hepatotoxicity. There are even studies
suggesting that statins may improve the liver disease
[71–74].
Monitoring of Diabetes
Many patients with diabetes are treated with lipid-lowering
drugs. Recent meta-analyses have shown an increased risk of
developing diabetes during statin treatment [75, 76]. The risk
is higher with high-dose statins [77, 78], in older patients and
in groups with known risk factors for diabetes. Statin therapy
was associated with a 9 % increased risk for incident diabe-
tes. Treatment of 255 patients with statins for 4 years resulted
in 1 extra case of diabetes [75]. The clinician should consider
screening for diabetes in patients with risk factors for devel-
oping diabetes [67, 79, 80].
Fibrates
Fibrates are in general well tolerated. Myopathy is reported
at a similar or even somewhat higher frequency compared
with statins [81]. Elevations of liver enzymes are also ob-
served. Consequently muscular symptoms and CK should be
monitored according to the same recommendations as for
statins (Table 3). Regular control of ALT is still recommend-
ed during fibrate treatment. Fibrates are also reported to raise
creatinine, but it is not clear whether this reflects change in
kidney function. Monitoring of creatinine is recommended
yearly for patients with risk factors such as type 2 diabetes or
already elevated creatinine levels [3•, 81]. Fibrates may also
increase homocysteine levels; this has not been shown to be
of clinical relevance, and monitoring of homocysteine is not
recommended.
Niacin
Elevated liver enzymes are also reported with niacin and
should be monitored as suggested for fibrates. Niacin may
increase blood glucose, which should be monitored in pa-
tients with diabetes or at risk of developing diabetes [44, 82,
83]. In combination with statin, niacin is associated with
increased risk of myopathy [46], and CK should be moni-
tored if muscle symptoms appear.
Ezetimibe and Bile Acid Sequestrants
Because the main site of action of these compounds is in the
intestine, they do not require any specific monitoring in
addition to their effects on plasma lipid levels [39, 84–86].
Safety Monitoring in the Elderly
The use of lipid-lowering drugs in the elderly is still a
controversial issue but available data suggest that hyperlip-
idemia should be treated according to the general guidelines
at least up to the age of 70. In a meta-analysis by the
Cholesterol Treatment Trialists'(CTT) collaboration, the re-
duction in cardiovascular end points was significant up to
age 75 years and also older, although only a few people were
included [28]. There are also data supporting statin treatment
in secondary prevention for patients above 80 years [87•].
The risk of side effects increases with age because of
organ dysfunction (liver and kidney) and polypharmacy with
the resulting increase in the potential for drug interactions
[67, 88]. Many drugs commonly used in the elderly interact
through the CYP3A system, which should be considered.
The doses should be adjusted and potential side effects
monitored more vigorously. High age is a risk factor for
severe myopathy, and clinicians should actively ask about
muscular symptoms; when positive, CK should be checked.
In the elderly, even minor muscle symptoms may seriously
affect the quality of life. Increased ALT is a common side
effect but this has not been found to be more common among
the elderly.
A few case reports on cognitive disturbances in the elderly
have been published [89]. At present, these reports are con-
sidered to be of minor significance and, according to the
FDA, should not support any changes in the use of statins
among the elderly [67].
Conclusions
Based on available risk algorithms and intervention trials, T-
C and LDL-C should be the first variables used to assess
cardiovascular risk. Other risk factors include HDL-C (an
important independent risk factor for cardiovascular dis-
ease), TG (an indicator of the metabolic status), and non-
HDL-C and apoB (which should especially be considered in
patients with hypertriglyceridemia or mixed hyperlipid-
emia). Other main risk factors (diabetes mellitus, smoking,
hypertension etc.) should also be considered to give an
overall cardiovascular risk assessment. New markers such
as Lp(a) and Lp-PLA2 are emerging as cardiovascular risk
factors, but future studies are required to understand how to
use these in clinical practice.
The primary treatment target in cardiovascular prevention
is LDL-C and potential alternative targets are apoB and non-
HDL-C. In selected high-risk individuals, TG should be
targeted with drug treatment, but HDL-C, Lp(a), and ratios
such as LDL-C/HDL-C or apoB/apoAI are not recommend-
ed as treatment targets. Lipids should be monitored during
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titration to targets and, thereafter, at least once a year or more
frequently to improve treatment adherence if indicated.
Monitoring of muscle and liver enzymes should be done
before the start of treatment. In stable conditions during
treatment, the focus should be on clinical symptoms that
may alert muscle or liver complications. Routine measure-
ment of CK or ALT is not necessary during treatment with
statins.
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